Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Army
US Department of Justice
Citi
Fuji
Cipla
Moodys
Colorcon
McKinsey

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021959

« Back to Dashboard

NDA 021959 describes ORAPRED ODT, which is a drug marketed by Concordia Pharms Inc and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the ORAPRED ODT profile page.

The generic ingredient in ORAPRED ODT is prednisolone sodium phosphate. There are eighty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.
Pharmacology for NDA: 021959
Suppliers and Packaging for NDA: 021959
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959 NDA Concordia Pharmaceuticals Inc. 59212-700 N 59212-700-48
ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959 NDA Concordia Pharmaceuticals Inc. 59212-701 N 59212-701-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 10MG BASE
Approval Date:Jun 1, 2006TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Nov 24, 2019Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 15MG BASE
Approval Date:Jun 1, 2006TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Nov 24, 2019Product Flag?YSubstance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 30MG BASE
Approval Date:Jun 1, 2006TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Nov 24, 2019Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021959

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 ➤ Sign Up ➤ Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 ➤ Sign Up ➤ Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 ➤ Sign Up ➤ Sign Up
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
US Department of Justice
Dow
Fuji
Cantor Fitzgerald
Johnson and Johnson
Baxter
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.